Topas Therapeutics Signs Multi-Year Research and Option Agreement with Lilly Focused on Immune Tolerance
In All, PortfolioWork will utilize Topas’ novel approach for antigen-specific tolerance induction Lilly has option to in-license and further develop drug candidates produced under the collaboration Hamburg, Germany, August 22, 2017 – Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private company, today announced that it has…